Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib + Venetoclax + Rituximab in Treatment Naïve Mantle Cell Lymphoma
NCT05951959Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2023
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of acalabrutinib tablet (Variant 1) in mantle cell lymphoma (MCL) (2 arms), sponsored by AstraZeneca. Primary endpoint: Minimal Residual Disease-negative Complete Response rate at Cycle 13. Started Dec 2023; status: active, not recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT05951959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05951959.